Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01133366 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin
A Phase 1 study, sponsored by Kastle Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01133366 is a Phase 1 study that has completed, run by Kastle Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT01133366, a Phase 1 study, has completed, sponsored by Kastle Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how blood clotting and thinning time is effected when a single dose of warfarin is given alone and when a single dose of warfarin is given with mipomersen; to assess the blood levels of a single dose of warfarin, a single dose of mipomersen, and a single dose of warfarin when given with mipomersen; and to assess the safety of mipomersen when given with or without warfarin.
Interventions
- DRUG warfarin sodium
- DRUG mipomersen sodium; warfarin sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01133366
The ClinicalTrials.gov registry entry for NCT01133366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kastle Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which warfarin sodium is the first listed.
NCT01133366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01133366 about?
NCT01133366 is a clinical study titled "A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin". The purpose of this study is to assess how blood clotting and thinning time is effected when a single dose of warfarin is given alone and when a single dose of warfarin is given with mipomersen; to assess the blood levels of a single dose of warfarin, a single dose of mipomersen, and a single dose o...
What is the current status of trial NCT01133366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-05. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01133366?
The interventions under investigation include: warfarin sodium (DRUG), mipomersen sodium; warfarin sodium (DRUG).
Who is sponsoring clinical trial NCT01133366?
This trial is sponsored by Kastle Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.